A B S T R A C T
Pseudomonas aeruginosa isolates (n = 183), collected from bacteraemic patients hospitalised in São Paulo Hospital (Brazil) during 2000-2001, were screened for susceptibility to antimicrobial agents. The polymyxins were the most active compounds (100% susceptibility), followed by amikacin and cefepime (59.0%), meropenem (57.4%), and imipenem and gentamicin (55.2%). Imipenem-resistant isolates were ribotyped and screened for production of metallo-b-lactamases (MBLs) by PCR with primers for bla IMP , bla VIM and bla SPM . MBL production was detected in 36 isolates (19.7% of the entire collection; 43.9% of the imipenem-resistant isolates) and the MBLs included SPM-1-like (55.6%), VIM-2-like (30.6%) and IMP-1-like (8.3%) enzymes. Pseudomonas aeruginosa is a leading cause of hospital-acquired infections that are often difficult to treat because of the limited choice of effective antimicrobial agents. Carbapenems, mainly imipenem and meropenem, are potent agents for the treatment of infections caused by multiresistant Gram-negative bacilli, especially P. aeruginosa. Resistance to carbapenems in P. aeruginosa has mostly been low level (MIC 8-32 mg ⁄ L), and associated with reduced uptake as a result of OprD porin loss [1] . Resistance by this mechanism depends on continued expression of the chromosomal AmpC b-lactamase. Low-level carbapenem resistance can also arise via over-expression of efflux pumps. However, production of metallob-lactamases (MBLs) is now being reported increasingly as a cause of high-level carbapenem resistance (MIC > 32 mg ⁄ L) in P. aeruginosa [1] [2] [3] . The MBL types are IMP, VIM and the recently described SPM [2] [3] [4] . The objective of the present study was to detect and characterise P. aeruginosa isolates producing MBLs in a teaching hospital located in Sao Paulo, Brazil.
The present study investigated all P. aeruginosa isolates (n = 183) from bloodstream infections (one isolate ⁄ patient) during 2000 and 2001 at the São Paulo Hospital complex, which is a 600-bed tertiary care university hospital. The isolates were tested initially by disk diffusion [5] against imipenem, meropenem, aztreonam, cefepime, ceftazidime, amikacin, gentamicin, ciprofloxacin and polymyxin B. All isolates that were nonsusceptible to imipenem or meropenem were then retested by broth microdilution (Trek Diagnostics Systems, East Grinstead, UK) according to NCCLS protocols [6] against the same group of antimicrobial agents (except that polymyxin B was replaced by colistin) plus piperacillin-tazobactam. Quality control strains were P. aeruginosa ATCC 27853, Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213. Isolates resistant to both imipenem and meropenem were screened initially for MBL production by the disk approximation test, with ceftazidime and imipenem as substrates, and EDTA and 2-mercaptopropionic acid as b-lactamase inhibitors [7] . The results were confirmed with Etest MBL strips (AB Biodisk, Solna, Sweden) [8] .
All isolates positive for MBL production were analysed by PCR for bla IMP-1 (sense 5¢-CTA-CCGCAGCAGAGTCTTTGC-3¢ and antisense 5¢-GAACAACCAGTTTTGCCTTACC-3¢ primers), bla VIM-1 (sense 5¢-TCTACATGACCGCGTCTGTC-3¢ and antisense 5¢-TGTGCTTTGACAACGTTCGC-3¢ primers), bla VIM-2 (sense 5¢-ATGTTCAAACTTTT-GAGTAGTAAG-3¢ and antisense 5¢-CTACTCAAC-GACT-GAGCG-3¢ primers) and bla SPM-1 (sense 5¢-CCTACAATCTAACGGCGACC-3¢ and antisense 5¢-TC-GCCGTGTCCAGGTATAAC-3¢ primers) under standard conditions [4] .
The genetic similarity of the 47 imipenemresistant isolates (MIC ‡ 16 mg ⁄ L) isolated in 2001 was investigated by automated ribotyping with the RiboPrinter Microbial Characterization System (DuPont de Nemours, Wilmington, DE, USA) [9] . In brief, this automated process includes lysis of overnight cell cultures, cleavage of DNA with the restriction enzyme PvuII, size separation by means of gel electrophoresis, and modified Southern blotting. Results were analysed with the Riboprinter system, and isolates were considered to have an identical ribotype if the similarity coefficient was ‡ 0.93.
Overall, 82 (44.8%) of 183 P. aeruginosa isolates from bloodstream infections in 2000 and 2001 were resistant to imipenem. The highest susceptibility (by disk diffusion) was to polymyxin B (100%), followed by amikacin and cefepime (59.0%), meropenem (57.4%), imipenem and gentamicin (55.2%), piperacillin-tazobactam (54.6%), ciprofloxacin (53.5%), ceftazidime (51.4%) and aztreonam (47.5%). Against imipenem-resistant isolates (n = 82), the most active compound was colistin or polymyxin E (MIC 90 £ 0.5 mg ⁄ L; 100% susceptible), followed by aztreonam (MIC 50 , 32 mg ⁄ L; 34.1% susceptible), cefepime (MIC 50 , 16 mg ⁄ L; 29.2% susceptible) and amikacin (MIC 50 , > 64 mg ⁄ L; 29.2% susceptible).
MBL production was detected in 36 isolates, representing 19.7% of the 183 isolates investigated, or 43.9% of the 82 imipenem-resistant isolates. Among the MBL-producing isolates, 20 (55.6%) were positive by PCR for bla SPM-1 , 11 (30.6%) were positive for bla VIM-2 , and three (8.3%) were positive for bla IMP-1 . Two (5.6%) isolates did not produce PCR amplification products with any of the primers used (Table 1) . Apart from the polymyxins (100% susceptibility), aztreonam (55.5% susceptibility) was the most active antimicrobial agent against the MBL-producing isolates. All isolates producing an SPM-1-like amplification product were susceptible to aztreonam. Susceptibilities to piperacillin-tazobactam and amikacin were 27.7% and 25.0%, respectively. All other compounds tested were active against < 15% of the 36 MBL-producing isolates.
Analysis of genetic similarity by ribotyping showed great clonal diversity among the 47 imipenem-resistant isolates collected in 2001. Twenty-five ribogroups were identified, and five of those were represented by more than one isolate (Table 1) . Seven ribogroups were identified among bla SPM-1 -positive isolates, three ribogroups were found among bla VIM-2 -positive isolates, and all three bla IMP-1 -positive isolates had distinct ribogroups.
Although the production of MBL is uncommon among clinical isolates of P. aeruginosa in other parts of the world, this mechanism is becoming increasingly more common in Brazil and other Latin American countries [10, 11] . After the first report of SPM-1 (São Paulo metallob-lactamase) in a P. aeruginosa isolate from this hospital (isolate 1088 in Table 1 ) [4] , this enzyme has disseminated throughout Brazil [10] .
The present study showed that P. aeruginosa isolates causing bloodstream infections in the São Paulo Hospital complex had high rates of resistance to most antimicrobial agents evaluated, and only the polymyxins showed consistent in-vitro activity. However, the role of aztreonam in the treatment of infections caused by isolates producing SPM-1-like enzymes should be evaluated further.
The correlation between carbapenem usage and resistance to these compounds has been difficult to establish [12] . Although the use of carbapenems in the São Paulo Hospital complex is restricted to treatment of infections caused by Gram-negative bacilli resistant to all other compounds, or for very special conditions, both imipenem and meropenem are now used routinely to treat P. aeruginosa infections because of the high rates of resistance to other compounds. The yearly usage of these two carbapenems combined varied from 1.7 to 3.8 g ⁄ 1000 patient-days in the entire hospital, and from 16.1 to 20.7 g ⁄ 1000 patient-days in the intensive care unit, during 1996-2001. In the same period, several clusters of infections caused by imipenem-resistant isolates with an identical or similar molecular fingerprinting pattern were identified. Thus, both factors (high usage of carbapenems and clonal dissemination of resistant strains) may be contributing to the increasing frequency of carbapenem-resistant P. aeruginosa in this hospital.
Production of MBLs represents an important mechanism of resistance to carbapenems and other b-lactams among P. aeruginosa isolates in this hospital. One in five P. aeruginosa isolates from bloodstream infections produced an MBL, and three types of MBL (IMP, VIM and SPM) were detected. The observed genetic diversity among isolates producing each type of MBL indicates that both horizontal and clonal dissemination of these genes has occurred in the hospital. Strict infection control measures should be implemented to prevent further spread of these potent MBLs.
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